Primary structure-based function characterization of BRCT domain replicates in BRCA1.

[1]  F. Collart,et al.  Efficient recognition of protein fold at low sequence identity by conservative application of Psi‐BLAST: application , 2005, Journal of molecular recognition : JMR.

[2]  Cheryl H Arrowsmith,et al.  Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein-protein and protein-DNA interactions? , 2005, Journal of molecular biology.

[3]  Olufunmilayo I Oloparde.  Genetics in clinical cancer care: a promise unfulfilled among minority populations. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  Michelle Webb,et al.  Purification and characterisation of a soluble N-terminal fragment of the breast cancer susceptibility protein BRCA1. , 2004, Journal of molecular biology.

[5]  S. Macura,et al.  Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. , 2004, Structure.

[6]  Lee Whitmore,et al.  DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data , 2004, Nucleic Acids Res..

[7]  Drew M. Lowery,et al.  Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer , 2004, Nature Structural &Molecular Biology.

[8]  C. Szabo,et al.  Understanding Germ-Line Mutations in BRCA1 , 2004, Cancer biology & therapy.

[9]  J. Glover,et al.  Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1 , 2004, Nature Structural &Molecular Biology.

[10]  Yigong Shi,et al.  Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. , 2004, Molecular cell.

[11]  L. Itzhaki,et al.  Comparison of BRCT domains of BRCA1 and 53BP1: A biophysical analysis , 2004, Protein science : a publication of the Protein Society.

[12]  B. Billack,et al.  Methods to Classify BRCA1 Variants of Uncertain Clinical Significance: The More the Merrier , 2004, Cancer biology & therapy.

[13]  P. Tompa,et al.  Binding‐induced folding transitions in calpastatin subdomains A and C , 2003, Protein science : a publication of the Protein Society.

[14]  P. Tompa.  Intrinsically unstructured proteins evolve by repeat expansion , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  E. Rosen,et al.  BRCA1 gene in breast cancer , 2003, Journal of cellular physiology.

[16]  D. Derbyshire,et al.  Purification, crystallization and preliminary X-ray analysis of the BRCT domains of human 53BP1 bound to the p53 tumour suppressor. , 2002, Acta crystallographica. Section D, Biological crystallography.

[17]  L. Serpell,et al.  Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor , 2002, The EMBO journal.

[18]  F. Collart,et al.  A new vector for high-throughput, ligation-independent cloning encoding a tobacco etch virus protease cleavage site. , 2002, Protein expression and purification.

[19]  N. C. Price,et al.  Conformational Analysis of the Androgen Receptor Amino-terminal Domain Involved in Transactivation , 2002, The Journal of Biological Chemistry.

[20]  A. Kentsis,et al.  Self-assembly properties of a model RING domain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Rachel E. Klevit,et al.  Structure of a BRCA1–BARD1 heterodimeric RING–RING complex , 2001, Nature Structural Biology.

[22]  A. Kentsis,et al.  PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA , 2001, The EMBO journal.

[23]  C B Begg,et al.  The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  C. Ponting,et al.  Protein repeats: structures, functions, and evolution. , 2001, Journal of structural biology.

[25]  C. Ponting,et al.  Homology-based method for identification of protein repeats using statistical significance estimates. , 2000, Journal of molecular biology.

[26]  D. Easton,et al.  Risk models for familial ovarian and breast cancer , 2000, Genetic epidemiology.

[27]  I. Irminger-Finger,et al.  The Functions of Breast Cancer Susceptibility Gene 1 (BRCA1) Product and Its Associated Proteins , 1999, Biological chemistry.

[28]  N. Shao,et al.  The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter , 1999, Oncogene.

[29]  Hui Tian,et al.  BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.

[30]  T. Ouchi,et al.  BRCA1 regulates p53-dependent gene expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[32]  Y. Houvras,et al.  Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl , 1997, Nature.

[33]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[34]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[35]  J. Mornon,et al.  From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair , 1997, FEBS letters.

[36]  Peer Bork,et al.  A superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteins , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  K. Dahlman-Wright,et al.  Structural characterization of a minimal functional transactivation domain from the human glucocorticoid receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Schaid,et al.  p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. , 1994, Oncogene.

[39]  M. Schiffer,et al.  Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[41]  K. Chew,et al.  Loss of heterozygosity and p53 gene mutations in breast cancer. , 1994, Cancer research.

[42]  M. Badzioch,et al.  Familial breast cancer risks. Effects of prostate and other cancers , 1993, Cancer.

[43]  F. Stevens.  Analysis of protein-protein interaction by simulation of small-zone size exclusion chromatography. Stochastic formulation of kinetic rate contributions to observed high-performance liquid chromatography elution characteristics. , 1989, Biophysical journal.

[44]  F. Stevens.  Analysis of protein-protein interaction by simulation of small-zone size-exclusion chromatography: application to an antibody-antigen association. , 1986, Biochemistry.

[45]  W. McGuire,et al.  Prognostic significance of p53 gene alterations in node-negative breast cancer , 2004, Breast Cancer Research and Treatment.

[46]  Lee Whitmore,et al.  DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra , 2002, Bioinform..

[47]  C. Ponting,et al.  The natural history of protein domains. , 2002, Annual review of biophysics and biomolecular structure.